Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases

• US 9,499,549 B2
• Filed: 10/09/2013
• Issued: 11/22/2016
• Est. Priority Date: 10/10/2012
• Status: Active Grant

• Current Assignee: Janssen Sciences Ireland UC (Johnson & Johnson)
• Original Assignee: Janssen Sciences Ireland UC (Johnson & Johnson)
• Inventors: McGowan, David Craig, Last, Stefaan Julien, Pieters, Serge Maria Aloysius, Embrechts, Werner, Jonckers, Tim Hugo Maria, Raboisson, Pierre Jean-Marie Bernard
• Primary Examiner(s): Balasubramanian, Venkataraman
• Application Number:
  US14/434,021
• Publication Number:
  US 20150239892A1
• Time in Patent Office: 1,140 Days
• Field of Search: 544/280, 514/259.1
• US Class Current: 1/1
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C07D 487/04 Ortho-condensed systems
• CPC Class Codes: C07D 519/00 Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

This invention concerns pyrrolo[3,2-d]pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treatment and/or therapy of diseases.

Claims

1. A compound of formula (I)

2. A compound as claimed in claim 1, wherein R₃ is methyl optionally substituted by aryl.

3. A compound as claimed in claim 1, wherein each of R₃ and R₄ is independently C_1-3 alkyl substituted by aryl.

4. A compound as claimed in claim 1, wherein R₁ is fluorine and R₂ is hydrogen.

5. A pharmaceutical composition comprising a compound as claimed in claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

6. A compound as claimed in claim 1, wherein R₃ is aryl-substituted C_1-3 alkyl and the aryl in said aryl-substituted C_1-3 alkyl is optionally substituted by one or more substituents independently selected from the group consisting of aryloxy, halogen, aryl, alkylamino, dialkylamino, C_1-6 alkyl, —

CO₂H, C(O)OC_1-6 alkyl, —

CONH₂, —

CN, and C_1-6 alkoxy; and

R₄ is aryl-substituted C_1-3 alkyl.